This study will utilize a randomized double-blind design to evaluate whether initial
treatment with two anti-depressant medications (escitalopram and bupropion) results in more
rapid remission and greater over-all remission rates than either monotherapy in 240 depressed
subjects.
Phase:
Phase 4
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborators:
National Institute of Mental Health (NIMH) University of Ottawa